azacitidine and valproic acid

azacitidine has been researched along with valproic acid in 86 studies

Research

Studies (86)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	24 (27.91)	29.6817
2010's	54 (62.79)	24.3611
2020's	8 (9.30)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Manev, H; Uz, T	1
Chen, CQ; Manev, H; Zhang, Z	1
Gudas, LJ; Mongan, NP	1
Garcia-Manero, G; Hoshino, K; Kantarjian, H; Sanchez-Gonzalez, B; Yang, H	1
Giles, FJ; Jabbour, E; Kantarjian, HM; Yee, KW	1
Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H	1
Mack, GS	1
Cortes, J; Estey, EH; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Issa, JP; Kantarjian, HM; Ouzounian, S; Pierce, S; Quezada, A; Ravandi, F; Soriano, AO; Wierda, WG; Yang, H	1
Blum, W; Byrd, JC; Chan, KK; Devine, H; Devine, SM; Grever, MR; Hackanson, B; Heerema, NA; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Lozanski, G; Marcucci, G; Murgo, A; Plass, C; Vukosavljevic, T	1
Bandzuchova, E; Kuba, D; Polakova, K; Russ, G; Tirpakova, J	1
Countryman, JK; Gradoville, L; Miller, G	1
Kuendgen, A; Lübbert, M	2
Ai, GW; Liu, W; Ma, XX; Meng, XQ; Meng, YS; Wei, R; Zhang, YX	1
Adès, L; Boehrer, S; de Botton, S; Fabre, C; Fenaux, P; Grosjean, J; Kroemer, G; Perfettini, JL; Tailler, M	1
Alexander, S; Braiteh, F; Garcia-Manero, G; Hong, D; Johnson, MM; Kurzrock, R; Silva, Lde P; Soriano, AO; Wolff, J; Yang, H	1
Garcia-Manero, G	1
Ito, M; Kondo, Y; Maeda, Y; Natsume, A; Oi, S; Saito, K; Shimato, S; Wakabayashi, T	1
Dullin, C; Ecke, I; Hahn, H; Hess, I; Johnsen, SA; Kimmina, S; Mönkemeyer, S; Nitzki, F; Petry, F; Pirngruber, J; Rosenberger, A; Schulz-Schaeffer, W; Tauber, S; Uhmann, A; Witt, O; Wojnowski, L	1
Blum, S; Gattermann, N; Germing, U; Haas, R; Habersang, K; Kuendgen, A; Möller, I	1
Alimena, G; Amadori, S; Angelucci, E; Borin, L; Buccisano, F; Cortelezzi, A; Di Tucci, A; Fabiani, E; Fazi, P; Finelli, C; Fioritoni, G; Gobbi, M; Leone, G; Liso, V; Martinelli, G; Maurillo, L; Musto, P; Petti, MC; Piciocchi, A; Pogliani, E; Santini, V; Vignetti, M; Voso, MT; Zini, G	1
Scott, BL	1
Biordi, L; Festuccia, C; Ficorella, C; Flati, V; Gravina, GL; Martella, F; Ricevuto, E; Tombolini, V	1
Jiang, J; Liu, XS; Peng, CY; Zheng, HT	1
Atala, A; Hodges, SJ; Mishra, N; Yoo, JJ	1
Eckschlager, T; Hrabeta, J; Hrebackova, J	1
Agathanggelou, A; Cavenagh, J; Craddock, C; Goodyear, O; McSkeane, T; Moss, P; Novitzky-Basso, I; Ryan, G; Siddique, S; Stankovic, T; Vyas, P	1
Chlenski, A; Cohn, SL; Godley, LA; Guerrero, LJ; Ostler, KR; Salwen, HR; Tian, Y; Yang, Q	1
Inoue, J; Ishida, T; Ito, T; Semba, K; Shimizu, T; Watanabe, S; Yamaguchi, N; Yamamoto, M	1
Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S	1
Chiarini, F; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Martelli, AM; Martinelli, G; Mongiorgi, S; Paolini, S; Ramazzotti, G	1
Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A	1
Clark, OH; Duh, QY; Griff, NJ; Grogan, RH; Kebebew, E; Mitmaker, EJ; Sarkar, R; Shen, WT	1
Calin, GA; Fang, Z; Garcia-Manero, G; Hu, Y; Kantarjian, HM; Wei, Y; Yang, H	1
Boëlle, PY; Chevret, S; Chomienne, C; Cras, A; Daniel, MT; de Labarthe, A; Degos, L; Dombret, H; Fenaux, P; Gardin, C; Maarek, O; Malfuson, JV; Marolleau, JP; Maury, S; Raffoux, E; Recher, C; Reman, O; Rousselot, P; Turlure, P; Victor, M	1
Cheong, SC; Gan, CP; Hamid, S; Hor, SY; Ismail, SM; Saunders, N; Teo, SH; Wan Mustafa, WM; Zain, RB	1
Blanquart, C; Boutin, B; Fonteneau, JF; Grégoire, M; Gueugnon, F; Guillot, F; Leclercq, S; Padieu, M; Pouliquen, D; Rogel, A	1
Kaminskyy, VO; Surova, OV; Vaculova, A; Zhivotovsky, B	1
Artemov, D; Carraway, H; Domek, J; Kato, Y; Kimble, B; Kowalski, J; Lisok, A; Raman, V; van der Groep, P; van Diest, P; Vesuna, F	1
Corsello, TR; Ma, Y; Yang, J	1
Blanquart, C; Fonteneau, JF; Grégoire, M; Gueugnon, F; Panterne, C; Roulois, D	1
Guo, J; Guo, L; Han, X; Li, J; Qu, Q; Sun, HD; Tan, WH; Yi, TZ	1
Bultmann, S; Elsaesser, J; Lahaye, T; Leonhardt, H; Morbitzer, R; Schmidt, CS; Spada, F; Thanisch, K	1
Chiaratti, MR; de Araújo, RR; De Bem, TH; Meirelles, FV; Oliveira, Lde J; Perecin, F; Sangalli, JR; Smith, LC; Valim Pimentel, JR	1
Cogdill, AP; Cooper, ZA; Ferrone, CR; Fiedler, A; Frederick, DT; Garber, HR; Rosenberg, L; Thayer, SP; Wargo, JA; Warshaw, AL	1
Chen, LH; Cheng, LY; Cherng, CG; Kao, GS; Su, CC; Tzeng, WY; Wang, CY; Yu, L	1
Aimiuwu, J; Chan, KK; Chu, BF; Grever, MR; Karpenko, MJ; Liu, Z; Otterson, GA; Villalona-Calero, MA	1
Baraty, C; Bianco, C; Castro, NP; Gonzales, M; Held, N; Karasawa, H; Rangel, MC; Rollman, K; Salomon, DS; Strizzi, L	1
Benayoun, E; Cordonnier, C; Maury, S; Pautas, C; Rahmé, R; Wagner-Ballon, O	1
Held, G; Kaddu-Mulindwa, D; Kubuschok, B; Neumann, F; Pfreundschuh, M; Preuss, KD; Roemer, K; Widmann, T; Zwick, C	1
Glasow, A; Kortmann, RD; Patties, I	1
Bustinza-Linares, E; Falchook, GS; Fu, S; Hong, DS; Hu, W; Kurzrock, R; Moulder, S; Naing, A; Parkhurst, KL; Sood, AK; Wheler, JJ	1
Gacek, A; Rychli, K; Strauss, J; Sulyok, M; Wagner, M; Zutz, C	1
Chavez, SL; Goyal, A; Reijo Pera, RA	1
Araki, H; Baluchamy, S; Lavelle, D; Li, X; Mahmud, N; Petro, B; Quigley, JG; Suphangul, M; Taioli, S	1
Gallagher, RC; Liu, J; Samuel, K; Turner, ML	1
Komandirov, MA; Sharifulina, SA; Uzdensky, AB	1
Hantash, BM; Purandare, B; Teklemariam, T; Zhao, L	1
Kouraklis, G; Nebiker, CA; Tampaki, EC; Tampakis, A	1
Borthakur, G; Brandt, M; Cortes, J; Garcia-Manero, G; Huang, X; Issa, JP; Jabbour, E; Kantarjian, HM; Pierce, S; Ravandi, F	1
Mukherjee, S; Ornstein, MC; Sekeres, MA	1
Cieslik, C; Döhner, K; Grishina, O; Hackanson, B; Lübbert, M; Lubrich, B; May, AM; Müller, MJ; Schmoor, C	1
Hoffman, R; Iancu-Rubin, C	1
Goes, FS; Ishizuka, K; Kano, S; Koga, M; Kondo, MA; Obie, C; Passeri, E; Primerano, A; Rapoport, JL; Sawa, A; Sengupta, S; Srivastava, R; Valle, D; Wilson, AM; Zandi, PP	1
Carter, CA; Day, RM; Lybeck, M; Oronsky, A; Oronsky, B; Oronsky, N; Richard, P; Scicinski, J; Zeman, K	1
Begaj, I; Boulet, S; Chevret, S; Jacob, L; Uvarova, M	1
Glasow, A; Kortmann, RD; Menzel, F; Patties, I	1
Coulie, PG; da Silva, M; Debets, R; Kunert, A; Lamers, C; Sleijfer, S; van Brakel, M; van Steenbergen-Langeveld, S	1
Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E	1
Chen, X; Huo, Y; Li, Y; Sun, J; Wang, T; Wang, W; Wu, J; Xi, W; Yang, A; Zheng, G	1
Frasca, F; Manzella, L; Massimino, M; Pennisi, MS; Puma, A; Romano, C; Sciacca, L; Stella, S; Tirrò, E; Vella, V; Vitale, SR	1
Desiderio, V; La Noce, M; Lombardi, A; Mele, L; Paino, F; Papaccio, F; Papaccio, G; Regad, T; Tirino, V	1
Hartung, EE; Mukhtar, SZ; Niles, LP; Shah, SM	1
Abiko, Y; Harada, F; Hiraki, D; Kurashige, Y; Morikawa, T; Neopane, P; Onishi, A; Paudel, D; Saitoh, M; Sato, J; Takai, R; Uehara, O; Yoshida, K	1
Adès, L; Amé, S; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Braun, T; Chermat, F; Chevret, S; Cheze, S; Cluzeau, T; de Botton, S; Dimicoli-Salazar, S; Duployez, N; Fenaux, P; Guerci-Bresler, A; Laribi, K; Marolleau, JP; Nimubona, S; Park, S; Peterlin, P; Preudhomme, C; Quesnel, B; Recher, C; Stamatoullas, A; Thepot, S; Toma, A; Vey, N; Wattel, E; Wickenhauser, S; Zerazhi, H	1
Seymour, JF; Wei, AH	1
Abiko, Y; Ariwansa, D; Harada, F; Khurelchuluun, A; Kurashige, Y; Morikawa, T; Onishi, A; Paudel, D; Takahashi, S; Uehara, O; Yoshida, K	1
Ainuddin, JA; Haneef, K; Naeem, N; Salim, A; Tarique, S	1
Akbar, N; Anum, H; Haneef, K; Razzaq, SS; Salim, A; Usman, S	1

Reviews

8 review(s) available for azacitidine and valproic acid

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Current status of epigenetic treatment in myelodysplastic syndromes. Annals of hematology, 2008, Volume: 87, Issue:8 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Valproic Acid	2008
Demethylating agents in myeloid malignancies. Current opinion in oncology, 2008, Volume: 20, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Leukemia; Myelodysplastic Syndromes; Risk; Treatment Outcome; Valproic Acid	2008
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Current medicinal chemistry, 2011, Volume: 18, Issue:5 Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1	2011
Histone deacetylase inhibitors and colorectal cancer: what is new? Anti-cancer agents in medicinal chemistry, 2014, Volume: 14, Issue:9 Topics: Antineoplastic Agents; Azacitidine; Colorectal Neoplasms; Combined Modality Therapy; Decitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Valproic Acid; Vorinostat	2014
More is better: combination therapies for myelodysplastic syndromes. Best practice & research. Clinical haematology, 2015, Volume: 28, Issue:1 Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat	2015
Role of epigenetic reprogramming in hematopoietic stem cell function. Current opinion in hematology, 2015, Volume: 22, Issue:4 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Proliferation; Cellular Reprogramming; Chromatin; Cytokines; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Lithium Chloride; Valproic Acid	2015
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget, 2016, Jun-28, Volume: 7, Issue:26 Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; CpG Islands; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Hydralazine; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Nitro Compounds; Nivolumab; Prognosis; Pyridines; Treatment Outcome; Valproic Acid	2016

Trials

16 trial(s) available for azacitidine and valproic acid

Article	Year
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood, 2006, Nov-15, Volume: 108, Issue:10 Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Valproic Acid	2006
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood, 2007, Oct-01, Volume: 110, Issue:7 Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; DNA Methylation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation; Histones; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; RNA, Messenger; Tretinoin; Valproic Acid	2007
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Diseases; Decitabine; Fatigue; Humans; Infections; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Remission Induction; Treatment Failure; Valproic Acid	2007
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-01, Volume: 14, Issue:19 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Cohort Studies; CpG Islands; DNA Methylation; Drug Synergism; Epigenesis, Genetic; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Valproic Acid	2008
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-01, Volume: 15, Issue:15 Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Azacitidine; Cytochrome P-450 CYP2C19; DNA Methylation; Drug Therapy, Combination; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Male; Methyltransferases; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Prognosis; Valproic Acid	2009
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Annals of hematology, 2011, Volume: 90, Issue:4 Topics: Adult; Aged; Azacitidine; Cytogenetic Analysis; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Modification Methylases; Epigenomics; Female; Histone Deacetylase Inhibitors; Humans; Hydralazine; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Valproic Acid; Young Adult	2011
Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia, 2011, Volume: 25, Issue:2 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Cells, Cultured; DNA Methylation; Drug Synergism; Enzyme Inhibitors; Epigenesis, Genetic; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Phosphoinositide Phospholipase C; Promoter Regions, Genetic; Signal Transduction; Valproic Acid	2011
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. American journal of hematology, 2011, Volume: 86, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; MicroRNAs; Myelodysplastic Syndromes; Treatment Outcome; Tretinoin; Valproic Acid	2011
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget, 2010, Volume: 1, Issue:1 Topics: Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; DNA, Neoplasm; Epigenomics; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymerase Chain Reaction; Survival Rate; Treatment Outcome; Tretinoin; Valproic Acid	2010
Treatment of nuclear-donor cells or cloned zygotes with chromatin-modifying agents increases histone acetylation but does not improve full-term development of cloned cattle. Cellular reprogramming, 2012, Volume: 14, Issue:3 Topics: Acetylation; Animals; Azacitidine; Cattle; Cell Nucleus; Cells, Cultured; Chromatin Assembly and Disassembly; Cloning, Organism; Decitabine; Embryonic Development; Female; Histone Deacetylase Inhibitors; Histones; Hydralazine; Hydroxamic Acids; Nuclear Transfer Techniques; Pregnancy; Term Birth; Up-Regulation; Valproic Acid; Zygote	2012
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Non-Small-Cell Lung; Decitabine; Dose-Response Relationship, Drug; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Valproic Acid	2013
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Investigational new drugs, 2013, Volume: 31, Issue:5 Topics: Acetylation; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; DNA Methylation; Female; Histone Deacetylase Inhibitors; Histones; Humans; Male; Middle Aged; Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Valproic Acid	2013
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer, 2015, Feb-15, Volume: 121, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes Theorem; Decitabine; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Valproic Acid	2015
DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute mye BMC cancer, 2015, May-26, Volume: 15 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Protocols; Decitabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Tretinoin; Valproic Acid	2015
Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology. BMC medical research methodology, 2016, 06-02, Volume: 16 Topics: Adult; Azacitidine; Bayes Theorem; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Research Design; Sample Size; Valproic Acid; Young Adult	2016
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. British journal of haematology, 2022, Volume: 198, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Idarubicin; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Valproic Acid	2022

Other Studies

62 other study(ies) available for azacitidine and valproic acid

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
DNA hypomethylating agents 5-aza-2'-deoxycytidine and valproate increase neuronal 5-lipoxygenase mRNA. European journal of pharmacology, 2002, Jun-07, Volume: 445, Issue:1-2 Topics: Animals; Arachidonate 5-Lipoxygenase; Azacitidine; Cells, Cultured; Cerebellum; Decitabine; DNA Methylation; Neurons; Rats; RNA, Messenger; Valproic Acid	2002
DNA methylation as an epigenetic regulator of neural 5-lipoxygenase expression: evidence in human NT2 and NT2-N cells. Journal of neurochemistry, 2004, Volume: 88, Issue:6 Topics: Arachidonate 5-Lipoxygenase; Azacitidine; Cell Differentiation; Cell Line; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Humans; Neurons; Promoter Regions, Genetic; RNA, Messenger; Teratocarcinoma; Valproic Acid	2004
Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Molecular cancer therapeutics, 2005, Volume: 4, Issue:3 Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Decitabine; DNA Primers; Enzyme Inhibitors; Histone Deacetylases; Histones; Humans; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Time Factors; Tretinoin; Valproic Acid	2005
Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leukemia research, 2005, Volume: 29, Issue:7 Topics: Antibiotics, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Primers; Drug Synergism; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, T-Cell; Reverse Transcriptase Polymerase Chain Reaction; Valproic Acid	2005
Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Annals of hematology, 2005, Volume: 84 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Administration Schedule; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; North America; Valproic Acid	2005
Epigenetic cancer therapy makes headway. Journal of the National Cancer Institute, 2006, Oct-18, Volume: 98, Issue:20 Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Hydroxamic Acids; Methyltransferases; Neoplasms; Randomized Controlled Trials as Topic; Valproic Acid; Vorinostat	2006
Modulation of HLA-G expression. Neoplasma, 2007, Volume: 54, Issue:6 Topics: Azacitidine; Base Sequence; Cell Hypoxia; Cell Line, Tumor; Decitabine; Enzyme Inhibitors; Epigenesis, Genetic; Flow Cytometry; Gene Expression; Gene Expression Regulation; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Hot Temperature; Humans; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Valproic Acid	2007
Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors. Journal of virology, 2008, Volume: 82, Issue:10 Topics: Acetylation; Animals; Azacitidine; Butyrates; Callithrix; Cell Line; Chromatin Immunoprecipitation; Decitabine; DNA Modification Methylases; DNA, Viral; Enzyme Inhibitors; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Tetradecanoylphorbol Acetate; Valproic Acid; Virus Activation; Virus Latency	2008
[Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell]. Zhonghua yi xue za zhi, 2007, Dec-25, Volume: 87, Issue:48 Topics: Acetylation; Adult; Aged; Azacitidine; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Histones; Humans; Leukemia; Middle Aged; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin; U937 Cells; Valproic Acid	2007
A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell cycle (Georgetown, Tex.), 2008, Jul-15, Volume: 7, Issue:14 Topics: Azacitidine; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Female; Granulocyte Precursor Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; I-kappa B Kinase; Leukemia, Myeloid, Acute; Male; Middle Aged; NF-kappa B; Valproic Acid	2008
Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells. Journal of neuro-oncology, 2009, Volume: 92, Issue:1 Topics: Antigens, Neoplasm; Azacitidine; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Synergism; Enzyme Inhibitors; Gene Expression; Glioma; Histone Deacetylase Inhibitors; Histones; Humans; Immunotherapy; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Valproic Acid	2009
Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer research, 2009, Feb-01, Volume: 69, Issue:3 Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression; Gene Silencing; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Medulloblastoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Muscle, Skeletal; Patched Receptors; Patched-1 Receptor; Receptors, Cell Surface; Rhabdomyosarcoma; Valproic Acid	2009
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine. Annals of hematology, 2009, Volume: 88, Issue:11 Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzene; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Drug Therapy, Combination; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Male; Occupational Exposure; Platelet Count; Quinolones; Thalidomide; Valproic Acid	2009
Clinical roundtable monograph. Combination therapies for MDS. Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:7 Topics: Azacitidine; Carrier Proteins; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colony-Stimulating Factors; Enzyme Inhibitors; Etanercept; Humans; Hydroxamic Acids; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Platelet Transfusion; Receptors, Fc; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Thalidomide; Thrombopoietin; Valproic Acid; Vorinostat	2009
Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. International journal of oncology, 2009, Volume: 35, Issue:5 Topics: Androgen Antagonists; Apoptosis; Azacitidine; Blotting, Western; Cells, Cultured; Epigenesis, Genetic; Gene Expression; Humans; Male; Polymerase Chain Reaction; Prostatic Neoplasms; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Valproic Acid	2009
Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines. Leukemia & lymphoma, 2010, Volume: 51, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Drug Antagonism; Drug Synergism; Electrophoresis, Capillary; Growth Inhibitors; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; K562 Cells; Leukemia; Oxides; U937 Cells; Valproic Acid	2010
The effect of epigenetic therapy on congenital neurogenic bladders--a pilot study. Urology, 2010, Volume: 75, Issue:4 Topics: Azacitidine; Cells, Cultured; Collagen; Epigenesis, Genetic; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Muscle, Smooth; Pilot Projects; Urinary Bladder; Urinary Bladder, Neurogenic; Valproic Acid	2010
Valproic acid in the complex therapy of malignant tumors. Current drug targets, 2010, Volume: 11, Issue:3 Topics: Acetylation; Angiogenesis Inhibitors; Apoptosis; Azacitidine; Cell Cycle; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Epilepsy; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53; Valproic Acid	2010
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood, 2010, Sep-16, Volume: 116, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Amino Acid Sequence; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cluster Analysis; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Male; Melanoma-Specific Antigens; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic; U937 Cells; Valproic Acid	2010
Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC cancer, 2010, Jun-14, Volume: 10 Topics: Acetylation; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Shape; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genotype; Histone Deacetylase Inhibitors; Histones; Humans; Neuroblastoma; Phenotype; Polymerase Chain Reaction; Promoter Regions, Genetic; Thrombospondin 1; Transfection; Valproic Acid	2010
Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer. Cancer science, 2010, Volume: 101, Issue:11 Topics: Acetylation; Azacitidine; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; CpG Islands; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; NF-kappa B; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Valproic Acid	2010
Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery, 2011, Volume: 149, Issue:4 Topics: Adenocarcinoma, Follicular; Adenocarcinoma, Papillary; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Thyroid Neoplasms; Valproic Acid	2011
Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head & neck, 2012, Volume: 34, Issue:3 Topics: Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Decitabine; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Squamous Cell Carcinoma of Head and Neck; Tretinoin; Valproic Acid	2012
A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma. The European respiratory journal, 2011, Volume: 38, Issue:5 Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mesothelioma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Pleural Neoplasms; T-Lymphocytes, Cytotoxic; Valproic Acid; Vorinostat	2011
Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis, 2011, Volume: 32, Issue:10 Topics: Azacitidine; Blotting, Western; Caspase 8; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Enzyme Inhibitors; Fluorescent Antibody Technique; Histone Deacetylases; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Membrane Potential, Mitochondrial; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Survivin; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Valproic Acid	2011
Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Oncogene, 2012, Jul-05, Volume: 31, Issue:27 Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Breast Neoplasms; Capillary Permeability; Cell Line, Tumor; Chromatin; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Down-Regulation; Drug Resistance, Neoplasm; E-Box Elements; Estrogen Receptor alpha; Estrogens; Female; Histone Deacetylase 1; Histones; Humans; Mice; Nuclear Proteins; Promoter Regions, Genetic; Protein Transport; RNA, Small Interfering; Tamoxifen; Twist-Related Protein 1; Valproic Acid	2012
Stem cell gene SALL4 suppresses transcription through recruitment of DNA methyltransferases. The Journal of biological chemistry, 2012, Jan-13, Volume: 287, Issue:3 Topics: Azacitidine; Cell Line, Tumor; CpG Islands; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Fibroblasts; Gene Silencing; HEK293 Cells; Hematopoietic Stem Cells; Histone Deacetylases; Humans; Promoter Regions, Genetic; PTEN Phosphohydrolase; Repressor Proteins; RNA, Messenger; Transcription Factors; Transcription, Genetic; Valproic Acid	2012
Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi. European journal of immunology, 2012, Volume: 42, Issue:3 Topics: Antigens, Neoplasm; Azacitidine; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Decitabine; Down-Regulation; Drug Therapy, Combination; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Kinetics; Membrane Proteins; Mesothelioma; Mucin-1; Real-Time Polymerase Chain Reaction; RNA; Statistics, Nonparametric; Valproic Acid	2012
DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo. Chemotherapy, 2012, Volume: 58, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cadherins; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Endometrial Neoplasms; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Mice; Mice, Nude; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Transplantation, Heterologous; Valproic Acid	2012
Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic acids research, 2012, Volume: 40, Issue:12 Topics: Animals; Azacitidine; Cells, Cultured; Decitabine; DNA Methylation; Embryonic Stem Cells; Enzyme Inhibitors; Epigenesis, Genetic; HEK293 Cells; Humans; Mice; Neural Stem Cells; Octamer Transcription Factor-3; Plasmids; Promoter Regions, Genetic; Trans-Activators; Transcriptional Activation; Valproic Acid	2012
Targeting the MAGE A3 antigen in pancreatic cancer. Surgery, 2012, Volume: 152, Issue:3 Suppl 1 Topics: Adenocarcinoma; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Cytokines; Decitabine; Deoxycytidine; DNA Methylation; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Male; Neoplasm Proteins; Pancreas; Pancreatic Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Testis; Valproic Acid	2012
Neonatal isolation decreases cued fear conditioning and frontal cortical histone 3 lysine 9 methylation in adult female rats. European journal of pharmacology, 2012, Dec-15, Volume: 697, Issue:1-3 Topics: Acoustic Stimulation; Age Factors; Animals; Animals, Newborn; Azacitidine; Behavior, Animal; Cerebral Cortex; Conditioning, Psychological; Corticosterone; Cues; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Down-Regulation; Estradiol; Fear; Female; Histone Deacetylase Inhibitors; Histones; Light; Lysine; Maternal Deprivation; Methylation; Photic Stimulation; Rats; Rats, Sprague-Dawley; Reflex, Startle; Stress, Psychological; Valproic Acid	2012
Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells. Journal of cellular physiology, 2013, Volume: 228, Issue:6 Topics: Azacitidine; Binding Sites; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Embryonal; Cell Movement; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Embryonal Carcinoma Stem Cells; Female; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Genes, Reporter; GPI-Linked Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Luciferases; MCF-7 Cells; Neoplasm Invasiveness; Neoplasm Proteins; Nuclear Receptor Subfamily 6, Group A, Member 1; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; RNA Interference; RNA, Messenger; Time Factors; Tissue Array Analysis; Transcription, Genetic; Transfection; Tretinoin; Valproic Acid	2013
Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report. Experimental hematology, 2013, Volume: 41, Issue:6 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Fatal Outcome; Female; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rituximab; Salvage Therapy; Transplantation, Homologous; Up-Regulation; Valproic Acid	2013
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. Cancer immunology, immunotherapy : CII, 2013, Volume: 62, Issue:7 Topics: Antigen-Presenting Cells; Antigens, Neoplasm; Azacitidine; B-Lymphocytes; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Transformed; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Interferon-gamma; Melanoma; Neoplasms; RNA, Messenger; Telomerase; Telomere; Tumor Necrosis Factor-alpha; Valproic Acid; Vorinostat	2013
Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines. Journal of experimental & clinical cancer research : CR, 2013, May-14, Volume: 32 Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Decitabine; DNA Breaks, Double-Stranded; Dose-Response Relationship, Drug; Epigenesis, Genetic; Humans; Medulloblastoma; Neoplasm Grading; Tretinoin; Tumor Stem Cell Assay; Valproic Acid	2013
Small chemical chromatin effectors alter secondary metabolite production in Aspergillus clavatus. Toxins, 2013, Oct-07, Volume: 5, Issue:10 Topics: Acetylglucosamine; Aspergillus; Azacitidine; Butyrates; Chromatin; Cytochalasins; Histone Deacetylase Inhibitors; Hydroxamic Acids; Methyltransferases; Patulin; Peptones; Pyrrolidinones; Valproic Acid	2013
Generation of human induced pluripotent stem cells using epigenetic regulators reveals a germ cell-like identity in partially reprogrammed colonies. PloS one, 2013, Volume: 8, Issue:12 Topics: Aurora Kinase B; Azacitidine; Blastocyst; Cell Differentiation; Cellular Reprogramming; Cluster Analysis; Colony-Forming Units Assay; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Embryonic Stem Cells; Epigenesis, Genetic; Fibroblasts; Gene Expression; Gene Expression Profiling; Gene Expression Regulation; Germ Cells; Histone-Lysine N-Methyltransferase; Histones; Homeodomain Proteins; Humans; Induced Pluripotent Stem Cells; Kruppel-Like Factor 4; Nanog Homeobox Protein; Protein-Arginine N-Methyltransferases; Telomerase; Transcription Factors; Transfection; Valproic Acid	2013
Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4 Topics: Animals; Antigens, CD34; Azacitidine; Cell Proliferation; Cells, Cultured; Decitabine; DNA Methylation; Epigenesis, Genetic; Fetal Blood; Gene Expression; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Mice, Inbred NOD; Mice, SCID; Thy-1 Antigens; Transplantation, Heterologous; Valproic Acid	2014
Use of IL3 and chromatin-modifying reagents valproic acid and 5-aza-2'-deoxycytidine to affect mobilized peripheral blood CD34+ cell fate decisions. Vox sanguinis, 2014, Volume: 107, Issue:1 Topics: Aged; Antigens, CD34; Azacitidine; Blood Cells; Cell Differentiation; Cells, Cultured; Chromatin; Colony-Forming Units Assay; Decitabine; Flow Cytometry; Hematopoietic Stem Cells; Humans; Interleukin-3; Male; Middle Aged; Valproic Acid	2014
Epigenetic regulation of death of crayfish glial cells but not neurons induced by photodynamic impact. Brain research bulletin, 2014, Volume: 102 Topics: Action Potentials; Animals; Apoptosis; Astacoidea; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Hydroxamic Acids; In Vitro Techniques; Indoles; Lasers; Mechanoreceptors; Necrosis; Neuroglia; Organometallic Compounds; Photic Stimulation; Photosensitizing Agents; Valproic Acid	2014
Inhibition of DNA methylation enhances HLA-G expression in human mesenchymal stem cells. Biochemical and biophysical research communications, 2014, Sep-26, Volume: 452, Issue:3 Topics: Adipose Tissue; Azacitidine; Bone Marrow Cells; Decitabine; DNA Methylation; Epigenesis, Genetic; HLA-G Antigens; Humans; Mesenchymal Stem Cells; Primary Cell Culture; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Valproic Acid	2014
Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges. Cancer, 2015, Feb-15, Volume: 121, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Treatment Failure; Valproic Acid	2015
Enhanced conversion of induced neuronal cells (iN cells) from human fibroblasts: Utility in uncovering cellular deficits in mental illness-associated chromosomal abnormalities. Neuroscience research, 2015, Volume: 101 Topics: Adolescent; Adult; Azacitidine; Cell Culture Techniques; Cell Differentiation; Chromosome Aberrations; Culture Media; Female; Fibroblasts; Humans; Hydroxamic Acids; Induced Pluripotent Stem Cells; Male; Middle Aged; Neural Stem Cells; Schizophrenia; Valproic Acid; Young Adult	2015
Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs. Journal of experimental & clinical cancer research : CR, 2016, 06-17, Volume: 35, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Combined Modality Therapy; Decitabine; Dideoxynucleosides; Epigenesis, Genetic; Humans; Hydroxamic Acids; Medulloblastoma; Mice; Neurogenesis; Radiation-Sensitizing Agents; Resveratrol; Stilbenes; Treatment Outcome; Tretinoin; Valproic Acid; Vorinostat; Xenograft Model Antitumor Assays	2016
MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses. Journal of immunology (Baltimore, Md. : 1950), 2016, 09-15, Volume: 197, Issue:6 Topics: Antigens, Neoplasm; Azacitidine; B7-1 Antigen; B7-2 Antigen; B7-H1 Antigen; Cell Line, Tumor; Epitopes, T-Lymphocyte; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Melanoma; Neoplasm Proteins; Receptors, Antigen, T-Cell; T-Lymphocytes; Valproic Acid	2016
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14 Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid	2017
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration. Medical science monitor : international medical journal of experimental and clinical research, 2018, Feb-19, Volume: 24 Topics: Apoptosis; Azacitidine; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Drug Synergism; G1 Phase; Humans; Kidney Neoplasms; Valproic Acid	2018
Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells. Anticancer research, 2018, Volume: 38, Issue:12 Topics: Animals; Azacitidine; Cells, Cultured; Combined Modality Therapy; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Rats; Rats, Inbred F344; Symporters; Thyroid Neoplasms; Transfection; Valproic Acid	2018
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy. Journal of experimental & clinical cancer research : CR, 2018, Dec-03, Volume: 37, Issue:1 Topics: Animals; Azacitidine; Bone Neoplasms; Cell Line, Tumor; DNA Methylation; Heterografts; Histone Deacetylase 2; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Osteosarcoma; Transfection; Valproic Acid	2018
5-Azacytidine upregulates melatonin MT Molecular biology reports, 2020, Volume: 47, Issue:6 Topics: Animals; Azacitidine; Cell Line; Cell Line, Tumor; Epigenesis, Genetic; Gene Expression; Gene Expression Regulation, Neoplastic; Glioma; Histone Deacetylase Inhibitors; Hydroxamic Acids; Melatonin; Rats; Receptor, Melatonin, MT1; Receptors, Melatonin; RNA, Messenger; Transcriptional Activation; Valproic Acid	2020
Direct reprogramming of epithelial cell rests of malassez into mesenchymal-like cells by epigenetic agents. Scientific reports, 2021, 01-20, Volume: 11, Issue:1 Topics: Animals; Azacitidine; Cell Dedifferentiation; Cell Survival; Cellular Reprogramming; Culture Media; Epithelial Cells; Mesenchymal Stem Cells; Swine; Transcription Factors; Valproic Acid	2021
Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes. British journal of haematology, 2022, Volume: 198, Issue:3 Topics: Azacitidine; Clinical Trials, Phase II as Topic; Humans; Idarubicin; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Valproic Acid	2022
Induction of Periodontal Ligament-like Cells by Coculture of Dental Pulp Cells, Dedifferentiated Cells Generated from Epithelial Cell Rests of Malassez, and Umbilical Vein Endothelial Cells. Journal of endodontics, 2022, Volume: 48, Issue:11 Topics: Azacitidine; Cell Differentiation; Cells, Cultured; Coculture Techniques; Dental Pulp; Endothelial Cells; Epithelial Cells; Humans; Periodontal Ligament; Rest; Umbilical Veins; Valproic Acid	2022
The role of epigenetic modifiers in the hepatic differentiation of human umbilical cord derived mesenchymal stem cells. Biologia futura, 2022, Volume: 73, Issue:4 Topics: Azacitidine; Cell Differentiation; Epigenesis, Genetic; Humans; Mesenchymal Stem Cells; Umbilical Cord; Valproic Acid	2022
Ascorbic acid and salvianolic acid B enhance the valproic acid and 5-azacytidinemediated cardiac differentiation of mesenchymal stem cells. Molecular biology reports, 2023, Volume: 50, Issue:9 Topics: Ascorbic Acid; Azacitidine; Cardiovascular Diseases; Cell Differentiation; Cells, Cultured; Humans; Mesenchymal Stem Cells; Myocytes, Cardiac; Valproic Acid	2023